105 patients fulfilling criteria of the International Study Group for BD4 were retrospectively included. Patients were categorized into two groups according to the presence (group 1) or absence (group 2) of neurological and/or psychiatric involvement. Patients with isolated headaches and those taking drugs and/or affected by disease known to induce CNS involvement were excluded from group 1. Group 1 was also divided into two subgroups according to neurological lesions type: patients with MP involvement, and those with cerebral vascular involvement (CV). Cerebrospinal fluid (CSF) analysis was performed in 19 patients. A pathergy test was performed in 27 patients (19 in group 1 and 8 in group 2) by intradermal needle pick and read after 24-48 hours. A cranial tomodensitometry scan was carried out for 19 patients (17 in group 1 and 2 in group 2). Cerebral MRI was performed in 24 patients (18 in group 1 and 6 in group 2). Genetic factors (HLA B51 and MICA6) were determined in 41 patients and 43 controls. HLA B51 allele was determined using a complement-dependent microlymphocyte toxicity assay, and triplet repeat polymorphism of MICA was analysed on a denaturating polyacrynamide gel, and alleles were visualised by autoradiography. Demographic, clinical and genetic features in all groups and subgroups were analysed and compared by Kruskall wallis and chi-square test. P value below 0.05 was considered statistically significant.
Was this article helpful?